Last reviewed · How we verify

Sigmart (nicorandil) — Competitive Intelligence Brief

Sigmart (nicorandil) (Sigmart (nicorandil)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel opener with nitrate-like properties. Area: Cardiovascular.

marketed Potassium channel opener with nitrate-like properties ATP-sensitive potassium channels (KATP) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sigmart (nicorandil) (Sigmart (nicorandil)) — Merck KGaA, Darmstadt, Germany. Nicorandil opens ATP-sensitive potassium channels in vascular smooth muscle and also has nitrate-like vasodilatory properties, reducing cardiac preload and afterload.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sigmart (nicorandil) TARGET Sigmart (nicorandil) Merck KGaA, Darmstadt, Germany marketed Potassium channel opener with nitrate-like properties ATP-sensitive potassium channels (KATP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel opener with nitrate-like properties class)

  1. Merck KGaA, Darmstadt, Germany · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sigmart (nicorandil) — Competitive Intelligence Brief. https://druglandscape.com/ci/sigmart-nicorandil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: